AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16687201 — intervention group
Group type: EXPERIMENTAL
Intervention: Single IUI performed 36 h after HCG administration combined with timed intercourse
Number of subjects: 94
Study 16687201 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI alone performed 36 h after HCG administration
Number of subjects: 94
Study 16687201 — intervention group
Group type: EXPERIMENTAL
Intervention: Double IUI performed 12 and 36 h after HCG administration
Number of subjects: 94
Study 14556831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer
Number of subjects: 2051
Study 14556831 — intervention group
Group type: COMPARATOR
Intervention: Clinical touch method
Number of subjects: 2051
Study 15635799 — intervention group
Group type: COMPARATOR
Intervention: IFN alpha 2 b (5MU sqm/daily)
Number of subjects: 43
Study 15635799 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha 2 b (5MU sqm/daily) plus monthly courses of low-dose AraC
Number of subjects: 43
Study 8844876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 0
Study 8844876 — intervention group
Group type: COMPARATOR
Intervention: Doxapram
Number of subjects: 0
Study 8844876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1626759 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen extract (10,000 BU)
Number of subjects: 10
Study 1626759 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine challenge
Number of subjects: 10
Study 1626759 — intervention group
Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 10
Study 6206105 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with a mean cumulative dose of cat allergen, 10.9 units
Number of subjects: 17
Study 6206105 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 17
Study 29101777 — intervention group
Group type: EXPERIMENTAL
Intervention: Real PENS therapy with etoricoxib, 3 times per week for 8 weeks
Number of subjects: 72
Study 29101777 — intervention group
Group type: COMPARATOR
Intervention: Sham PENS therapy with etoricoxib, 3 times per week for 8 weeks
Number of subjects: 72
Study 30341123 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth tools including satellite communications
Number of subjects: 0
Study 27449712 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, etoposide, and carboplatin (VEC)
Number of subjects: 54
Study 27449712 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and etoposide, alternating with cyclophosphamide, idarubicin, and vincristine
Number of subjects: 54
Study 25170535 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic midurethral sling (RP)
Number of subjects: 54
Study 25170535 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator midurethral sling (TO)
Number of subjects: 54
Study 22577748 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 0
Study 22577748 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study 19524262 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg Parecoxib
Number of subjects: 32
Study 19524262 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline solution
Number of subjects: 32
Study 18030450 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (1 mg DMT kg(‐1) body weight)
Number of subjects: 22
Study 18030450 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine (20 mg)
Number of subjects: 22
Study 18030450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15223094 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) - 3 sessions
Number of subjects: 71
Study 15223094 — intervention group
Group type: COMPARATOR
Intervention: Educational videos and home visit - 2 videos and 1 home visit
Number of subjects: 71
Study 11403190 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcised white men
Number of subjects: 532
Study 11403190 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncircumcised Hispanic men
Number of subjects: 532
Study 11403190 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncircumcised white men
Number of subjects: 532
Study 11403190 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncircumcised black men
Number of subjects: 532
Study 11403190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician gender (both women)
Number of subjects: 532
Study 9586596 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg
Number of subjects: 6
Study 9586596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8024729 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet therapy for 15 months
Number of subjects: 71
Study 2509380 — intervention group
Group type: EXPERIMENTAL
Intervention: TDN 20 (transdermal nitroglycerin patches, 20 mg over 24 h)
Number of subjects: 10
Study 2509380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2509380 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic TDN treatment
Number of subjects: 10
Study 911371 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy group (clofibrate 1 g twice daily and nicotinic acid 1 g three times daily)
Number of subjects: 558
Study 911371 — intervention group
Group type: COMPARATOR
Intervention: Control group (moderate diet advice only)
Number of subjects: 558
Study 29377141 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-neutral vaccination with AS04-adjuvanted HPV16/18 vaccine (Arm A)
Number of subjects: 11675
Study 29377141 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination of girls and hepatitis B-virus (HBV) vaccination of boys (Arm B)
Number of subjects: 11675
Study 29377141 — intervention group
Group type: COMPARATOR
Intervention: Gender-neutral HBV vaccination (Arm C)
Number of subjects: 11675
Study 27780487 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 0
Study 24689255 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical simulation of an underground bolting machine
Number of subjects: 48
Study 24689255 — intervention group
Group type: COMPARATOR
Intervention: Virtual simulation of a generic device
Number of subjects: 48
Study 21923735 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 63
Study 21923735 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction plus exercise (CR+EX)
Number of subjects: 63
Study 21923735 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 63
Study 20042557 — intervention group
Group type: EXPERIMENTAL
Intervention: Light sedation (BIS >or=80)
Number of subjects: 114
Study 20042557 — intervention group
Group type: COMPARATOR
Intervention: Deep sedation (BIS approximately 50)
Number of subjects: 114
Study 18852481 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Combined Treatment (SCT)
Number of subjects: 209
Study 18852481 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TU)
Number of subjects: 209
Study 15730352 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.5 mg per week
Number of subjects: 60
Study 15730352 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times daily
Number of subjects: 60
Study 15730352 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydergine 1 mg three times daily
Number of subjects: 60
Study 15730352 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 25/100 mg three times daily
Number of subjects: 60
Study 14522476 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (ABC)
Number of subjects: 1780
Study 14522476 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENOX)
Number of subjects: 1780
Study 14522476 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 1780
Study 10979909 — intervention group
Group type: EXPERIMENTAL
Intervention: II CPS-TT conjugate vaccine (dose range, 3.6-57 microg of CPS component)
Number of subjects: 75
Study 10979909 — intervention group
Group type: COMPARATOR
Intervention: Uncoupled II CPS vaccine
Number of subjects: 75
Study 8684103 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 1,5-anhydroglucitol (1,5AG) monitoring in group A (continuous treatment)
Number of subjects: 56
Study 8684103 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 1,5-anhydroglucitol (1,5AG) monitoring in group B (intermittent treatment)
Number of subjects: 56
Study 8684103 — intervention group
Group type: COMPARATOR
Intervention: Fasting plasma glucose (FPG) monitoring
Number of subjects: 56
Study 8684103 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of 1,5AG with FPG and mean daily plasma glucose
Number of subjects: 56
Study 1611648 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef 400 mg twice daily for 10 to 14 days
Number of subjects: 134
Study 1611648 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 500/125 mg three times daily for 10 to 14 days
Number of subjects: 134
Study 6705901 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose antidepressants (75 mg/day)
Number of subjects: 370
Study 6705901 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose antidepressants (150 mg/day)
Number of subjects: 370
Study 30158392 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia
Number of subjects: 60
Study 30158392 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 60
Study 29653644 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting, durable polymer-coated Resolute Onyx stent
Number of subjects: 2470
Study 29653644 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting, bioresorbable polymer-coated Orsiro stent
Number of subjects: 2470
Study 26243733 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) delivered by promotores
Number of subjects: 698
Study 26243733 — intervention group
Group type: COMPARATOR
Intervention: Assessed condition (control)
Number of subjects: 698
Study 25321641 — intervention group
Group type: EXPERIMENTAL
Intervention: CSRP services (multicomponent, classroom‐based mental health intervention)
Number of subjects: 0
Study 22571507 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin (Arm C)
Number of subjects: 110
Study 22571507 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (Arm B)
Number of subjects: 110
Study 22571507 — intervention group
Group type: COMPARATOR
Intervention: No antifungal treatment (Arm A)
Number of subjects: 110
Study 20195154 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart‐Age message
Number of subjects: 413
Study 20195154 — intervention group
Group type: COMPARATOR
Intervention: Percentage risk message
Number of subjects: 413
Study 17591019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 24
Study 17591019 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 24
Study 17591019 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 24
Study 17591019 — intervention group
Group type: COMPARATOR
Intervention: Comparison of patients to HCs at week 96
Number of subjects: 24
Study 15764869 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabeluzole
Number of subjects: 0
Study 15764869 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 0
Study 15764869 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver assistance
Number of subjects: 0
Study 15764869 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver type
Number of subjects: 0
Study 11837553 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 2 mg orally under fasting conditions
Number of subjects: 30
Study 11837553 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 2 mg orally after a high-fat meal
Number of subjects: 30
Study 11837553 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 2.5 mg/day orally in patients with renal transplants under fasting conditions
Number of subjects: 30
Study 11837553 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 2.5 mg/day orally in patients with renal transplants after a high-fat meal
Number of subjects: 30
Study 11837553 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus trough levels
Number of subjects: 30
Study 11837553 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak-trough fluctuation of everolimus
Number of subjects: 30
Study 10091411 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Number of subjects: 46
Study 10091411 — intervention group
Group type: COMPARATOR
Intervention: Control (no rhGM-CSF)
Number of subjects: 46
Study 8672324 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (serum concentrations > or = 200 kiu ml‐1)
Number of subjects: 52
Study 8672324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 3661477 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Number of subjects: 21
Study 3661477 — intervention group
Group type: COMPARATOR
Intervention: Control group (no taurine supplementation)
Number of subjects: 21
Study 29321047 — intervention group
Group type: EXPERIMENTAL
Intervention: MAG‐EPA supplementation (6 capsules of 625 mg of fish oil daily, containing 500 mg of EPA)
Number of subjects: 130
Study 29321047 — intervention group
Group type: EXPERIMENTAL
Intervention: MAG‐EPA supplementation
Number of subjects: 130
Study 29321047 — intervention group
Group type: COMPARATOR
Intervention: Placebo (high oleic acid sunflower oil)
Number of subjects: 130
Study 26526300 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TNA) applied during and after intense pulsed light (IPL) treatment.
Number of subjects: 15
Study 26526300 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control) applied during and after intense pulsed light (IPL) treatment.
Number of subjects: 15
Study 25391867 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 270, low tube output, iterative reconstruction (SAFIRE)
Number of subjects: 120
Study 25391867 — intervention group
Group type: COMPARATOR
Intervention: Iopromide 370, conventional tube output, filtered back projection (FBP)
Number of subjects: 120
Study 25391867 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Iodixanol 270 and Iopromide 370)
Number of subjects: 120
Study 23573081 — intervention group
Group type: EXPERIMENTAL
Intervention: MyCPAP website intervention
Number of subjects: 0
Study 23573081 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC, control)
Number of subjects: 0
Study 20723998 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal depression severity
Number of subjects: 69
Study 20723998 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor maternal sleep
Number of subjects: 69
Study 18761570 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink II
Number of subjects: 120
Study 18761570 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemiace II
Number of subjects: 120
Study 18761570 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-Bond C&B
Number of subjects: 120
Study 18761570 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F
Number of subjects: 120
Study 20499339 — intervention group
Group type: EXPERIMENTAL
Intervention: SQSTM1 mutation carriers
Number of subjects: 737
Study 16369731 — intervention group
Group type: EXPERIMENTAL
Intervention: bLF tablets at a dosage of 200 mg b.i.d. for a period of 12 weeks
Number of subjects: 59
Study 16369731 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets without bLF
Number of subjects: 59
Study 11561799 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg daily for 3 days
Number of subjects: 265
Study 11561799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 9396979 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 60 mg bid
Number of subjects: 570
Study 9396979 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 120 mg bid
Number of subjects: 570
Study 9396979 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 240 mg bid
Number of subjects: 570
Study 9396979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study 7954759 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan
Number of subjects: 230
Study 7954759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 3812344 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive alcohol consumption (case men)
Number of subjects: 26
Study 3812344 — intervention group
Group type: COMPARATOR
Intervention: Control men
Number of subjects: 26
Study 11800042 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBDNF (25 microg/kg)
Number of subjects: 30
Study 11800042 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBDNF (100 microg/kg)
Number of subjects: 30
Study 11800042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31718402 — intervention group
Group type: EXPERIMENTAL
Intervention: Geisinger Maternal Fetal Medicine obesity protocol (MOP)
Number of subjects: 97
Study 30876777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal mesotherapy with tenoxicam
Number of subjects: 0
Study 30876777 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexketoprofen (control)
Number of subjects: 0
Study 29207249 — intervention group
Group type: EXPERIMENTAL
Intervention: Supporting Physical Activity in the Childcare Environment (SPACE) intervention
Number of subjects: 234
Study 29207249 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 234
Study 27424229 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding with Renutryl® Booster (600 kcal, 30g protein, 72g carbohydrate, 21g fat) for 2 weeks
Number of subjects: 30
Study 27424229 — intervention group
Group type: COMPARATOR
Intervention: Control group (BMI 20-25 kg/m2)
Number of subjects: 30
Study 24964886 — intervention group
Group type: EXPERIMENTAL
Intervention: Imageless navigation
Number of subjects: 125
Study 24964886 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy
Number of subjects: 125
Study 22140199 — intervention group
Group type: COMPARATOR
Intervention: Computer-based compensatory therapy (CT)
Number of subjects: 45
Study 22140199 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative computerized training (RT)
Number of subjects: 45
Study 22140199 — intervention group
Group type: COMPARATOR
Intervention: Standard occupational therapy (OT)
Number of subjects: 45
Study 20206437 — intervention group
Group type: EXPERIMENTAL
Intervention: U-type method of TVT SECUR
Number of subjects: 285
Study 20206437 — intervention group
Group type: COMPARATOR
Intervention: H-type method of TVT SECUR
Number of subjects: 285
Study 17272964 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5-10 mg)
Number of subjects: 21
Study 17272964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 17272964 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 21
Study 16376775 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous mitral commissurotomy (PMC)
Number of subjects: 120
Study 12063921 — intervention group
Group type: EXPERIMENTAL
Intervention: New immediate early management prosthesis with individually adjustable air chambers
Number of subjects: 0
Study 12063921 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical cadaver study with the prostheses
Number of subjects: 0
Study 9468082 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 degrees tilt protocol
Number of subjects: 0
Study 9468082 — intervention group
Group type: EXPERIMENTAL
Intervention: edrophonium provocation
Number of subjects: 0
Study 9468082 — intervention group
Group type: EXPERIMENTAL
Intervention: isoproterenol challenge
Number of subjects: 0
Study 7892894 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 to 80 mg daily from 12 weeks' gestation until delivery)
Number of subjects: 24
Study 7892894 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 24
Study 7892894 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 24
Study 2711266 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration of amoebic liver abscess (ALA)
Number of subjects: 80
Study 2711266 — intervention group
Group type: COMPARATOR
Intervention: Non-aspiration
Number of subjects: 80
Study 1111463 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent courses of carmustine with prednisone
Number of subjects: 508
Study 1111463 — intervention group
Group type: EXPERIMENTAL
Intervention: continued courses of melphalan with prednisone
Number of subjects: 508
Study 1111463 — intervention group
Group type: COMPARATOR
Intervention: no chemotherapy
Number of subjects: 508
Study 1111463 — intervention group
Group type: EXPERIMENTAL
Intervention: continued melphalan-prednisone chemotherapy
Number of subjects: 508
Study 31242506 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief mindfulness intervention (BMG)
Number of subjects: 234
Study 31242506 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude journal intervention (GJG)
Number of subjects: 234
Study 31242506 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 234
Study 28084175 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidiabetic drugs (including metformin)
Number of subjects: 78615
Study 28084175 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 78615
Study 28084175 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylureas
Number of subjects: 78615
Study 28084175 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones or insulin
Number of subjects: 78615
Study 28084175 — intervention group
Group type: COMPARATOR
Intervention: Non-users of antidiabetic drugs
Number of subjects: 78615
Study 25356749 — intervention group
Group type: EXPERIMENTAL
Intervention: Live presentation mode; emotional demeanor
Number of subjects: 81
Study 25356749 — intervention group
Group type: COMPARATOR
Intervention: Video presentation mode; emotional demeanor
Number of subjects: 81
Study 25356749 — intervention group
Group type: EXPERIMENTAL
Intervention: Live presentation mode; neutral demeanor
Number of subjects: 81
Study 25356749 — intervention group
Group type: COMPARATOR
Intervention: Video presentation mode; neutral demeanor
Number of subjects: 81